Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Your view on AQST
Overview
What the company does, where it operates, and who runs it.
About Aquestive Therapeutics, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Daniel Barber
- Headquarters
- 30 Technology Drive, Warren, NJ, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Daniel Barber
- Headquarters
- 30 Technology Drive, Warren, NJ, US
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.
The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis.
Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Aquestive Therapeutics, Inc. from FRC's valuation model, read against the market price. AQST last traded at $3.76; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aquestive Therapeutics, Inc.. Starting points for Aquestive Therapeutics, Inc.: EPS -$0.63, beta 1.50 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Aquestive Therapeutics, Inc.. Aquestive Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aquestive Therapeutics, Inc.. Trailing twelve-month EPS for Aquestive Therapeutics, Inc. stands at -$0.63. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$9.75
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy10
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.11 | -$0.13 | -$0.47 | -$0.49 |
| Low estimate | -$0.13 | -$0.17 | -$0.52 | -$0.62 |
| High estimate | -$0.09 | -$0.11 | -$0.44 | -$0.40 |
| No. of analysts | 2 | 1 | 4 | 4 |
| Year-ago EPS | -$0.261 | -$0.07 | -$0.761 | — |
| Growth | — | -83.3% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $13.70M | $12.43M | $49.50M | $67.91M |
| Low estimate | $13.04M | $11.88M | $48.71M | $64.49M |
| High estimate | $14.89M | $12.98M | $50.29M | $72.81M |
| No. of analysts | 6 | 3 | 6 | 7 |
| Year-ago revenue | $13.02M | $14.45M | $44.55M | — |
| Growth | +5.2% | -14.0% | +11.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aquestive Therapeutics, Inc.. Aquestive Therapeutics, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
- AMPHAmphastar Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.2B
- AYTUAytu BioPharma, Inc.Drug Manufacturers - Specialty & Generic$20M
- COLLCollegium Pharmaceutical, Inc.Drug Manufacturers - Specialty & Generic$790M
- CPIXCumberland Pharmaceuticals Inc.Drug Manufacturers - Specialty & Generic$78M
- DERMJourney Medical CorporationDrug Manufacturers - Specialty & Generic$104M
- SUPNSupernus Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$6.0B
- VNDAVanda Pharmaceuticals Inc.Biotechnology$230M
More Drug Manufacturers - Specialty & Generic companies
- NPPNYNippon Shinyaku Co., Ltd.OTC$2.3B
- NSRSNorth Springs Resources CorpOTC$35,902
- NUGSCannabis Strategic VenturesOTC$187,588
- NXENNexien BioPharma, Inc.OTC$7,077
- OGIOrganigram Global Inc.NASDAQ$102M
- OGI.TOOrganiGram Holdings Inc.TSX$147M
- OILFFNextleaf Solutions Ltd.OTC$6M
- OILS.CNNextleaf Solutions Ltd.CNQ$8M
- OMIDOMID Holdings, Inc.OTC
- OPTHOptimi Health Corp.NASDAQ$13M
- OPTI.CNOptimi Health Corp.CNQ$27M
- ORGOOrganogenesis Holdings Inc.NASDAQ$104M
ETFs holding Aquestive Therapeutics, Inc.
% of the fund
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets0.99%
- VXFVanguard Extended Market ETF$30.2B in assets0.01%
- SURISimplify Propel Opportunities ETF$70M in assets1.53%
- FSCCFederated Hermes MDT Small Cap Core ETF$496M in assets0.24%
- IWCiShares Micro-Cap ETF$1.2B in assets0.11%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.02%
Largest holders first, then the funds most concentrated in AQST.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aquestive Therapeutics, Inc., and how their positions are changing. At a $472.6M market value, institutional positions materially move Aquestive Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aquestive Therapeutics, Inc. executives and directors. Shares of Aquestive Therapeutics, Inc. have traded between $2.12 and $7.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aquestive Therapeutics, Inc.. Coverage tracks Aquestive Therapeutics, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aquestive Therapeutics, Inc.